Phase I/II Study of SCTB39G in Advanced Solid Tumours

Summary

This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB39G as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.

Timeline

Start

2025-07-28

Primary completion

2027-09-26

Completion

2027-10-17

Drugs

Indications